Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Efficacy of Methylene blue mediated Photodynamic therapy for primary localized cutaneous amyloidosis treatment in Asians, pilot study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lichen Amyloidosis Amyloidosis, Primary Cutaneous

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

King Chulalongkorn Memorial Hospital

Bangkok, 10330, Thailand

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients, aged > 18 years old with lichen amyloidosis diagnosed by using clinical presentation and pathological findings.

Exclusion criteria

Those with systemic disease associated cutaneous amyloidosis
Pregnancy or lactating woman
Those who are allergic to urea, olive oil
Those who are photosensitive to ultraviolet radiation
Those who had been previously treated with any of which -medications, radiation, laser within 3 months and 1 month for topical therapy

Treatment and study plan

Methylene blue-mediated photodynamic therapy

Procedure

The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)

Primary outcomes

Roughness evaluation by using visioscan

Time frame: Change from baseline roughness at every 2 weeks up to 16 weeks

The improvement of roughness during the treatment

Sponsors and collaborators

Lead sponsor

Chulalongkorn University

Other

Registry information

Official study title

Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians: Pilot Study

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Mar 1, 2017
Registry last updated: May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed